Related Experiment Videos
Development of radicicol analogues.
Shiro Soga1, Yukimasa Shiotsu, Shiro Akinaga
1Pharmaceutical Research Institute, Kyowa Hakko Kogyo Co., Ltd., 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka-ken 411-8731, Japan.
Current Cancer Drug Targets
|October 8, 2003
Summary
Radicicol oxime derivatives effectively inhibit tumors by targeting Hsp90, depleting client proteins, and inducing apoptosis. These compounds show promise against ErbB2-overexpressing breast cancer and Bcr-Abl-positive CML.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Radicicol, a fungal antibiotic, inhibits tyrosine kinases and signal transduction pathways.
- It targets Hsp90 (heat shock protein 90) by binding to its ATP-binding site, depleting client signaling molecules.
- Radicicol's in vivo instability limits its therapeutic use.
Purpose of the Study:
- To evaluate the antitumor potential of radicicol oxime derivatives.
- To investigate the mechanism of action of these derivatives against specific cancers.
Main Methods:
- Yeast and mammalian cell-based assays to study signal transduction inhibition.
- In vivo studies using human tumor xenograft models.
- Analysis of Hsp90 client protein depletion and apoptosis induction in tumor tissues.
Main Results:
- Radicicol oxime derivatives demonstrated potent antitumor activity in xenograft models.
- Treatment led to depletion of Hsp90 client proteins and induced apoptosis in tumors.
- Effective against ER-negative/ErbB2-overexpressing breast cancer and Bcr-Abl-expressing CML.
Conclusions:
- Radicicol oxime derivatives exert antitumor effects by inhibiting Hsp90 and destabilizing its client proteins.
- These derivatives represent a promising therapeutic strategy for specific cancers like breast cancer and CML.